FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.739,50 -1.270,38 (-2,12%)
Sunshine Biopharma, Inc. (SBFM)
Dopo ore:
| Chiusura precedente | 0,8074 |
| Aperto | 0,7720 |
| Denaro | 1,0900 x 100 |
| Lettera | 1,6500 x 300 |
| Min-Max giorno | 0,7531 - 1,1900 |
| Intervallo di 52 settimane | 0,7500 - 140,0000 |
| Volume | |
| Media Volume | 1.643.073 |
| Capitalizzazione | 944.801 |
| Beta (5 anni mensile) | -1,11 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -19,0000 |
| Prossima data utili | 09 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 300,00 |
GlobeNewswireSunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter. The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022. The increase was largely due to the
- GlobeNewswire
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 16, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expens
- GlobeNewswire
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Com
